Nexavar Related Clinical Trials
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv.) Renal Cell Carcinoma (RCC) [Completed]
BAY 43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma [Active, not recruiting]
Sorafenib in Resected Non-Small Cell Lung Carcinoma [Active, not recruiting]
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) [Not yet recruiting]
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib [Recruiting]
Phase III Study of BAY 43-9006 in Japanese Patients With Advanced Hepatocellular Carcinoma [Active, not recruiting]
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) [Recruiting]
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer [Recruiting]
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma [Recruiting]
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer [Recruiting]
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma [Recruiting]
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [Recruiting]
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent [Recruiting]
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer [Recruiting]
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients [Recruiting]
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone [Recruiting]
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas [Recruiting]
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer [Recruiting]
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome [Recruiting]
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors [Recruiting]
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan [Recruiting]
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE [Recruiting]
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone [Recruiting]
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. [Recruiting]
Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer [Recruiting]
Extension Program for Bay 43-9006 [Completed]
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC [Recruiting]
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer [Recruiting]
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma [Not yet recruiting]
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) [Recruiting]
Effect op Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 [Recruiting]
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) [Recruiting]
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma [Recruiting]
Cisplatin/Etoposide/Radiotherapy With Sorafenib + Consolidation Sorafenib for Inoperable Stage III NSCLC [Suspended]
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma [Recruiting]
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer [Recruiting]
Vemurafenib and Sorafenib in Advanced Cancer [Recruiting]
Sorafenib for Patients With Extensive Keloids [Not yet recruiting]
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination [Recruiting]
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec [Completed]
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer [Not yet recruiting]
SORAVE - Sorafenib and Everolimus in Solid Tumors [Recruiting]
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Recruiting]
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma [Recruiting]
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas [Recruiting]
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation [Recruiting]
BAY43-9006 - Phase II in Advance Breast Cancer [Active, not recruiting]
A Study to Estimate Safety and Efficacy of Bay 43-9006 in the Treatment of Hepatocellular Carcinoma [Active, not recruiting]
Phase III Study of Sorafenib in Patients With RCC
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma [Active, not recruiting]
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer [Active, not recruiting]
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies [Suspended]
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma [Active, not recruiting]
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) [Active, not recruiting]
Clinical Trial on the Mixture of Gemcitabine, Capecitabine, and Sorafenib (Bay 43-9006) in the Treatment of Patients With Renal Cell Carcinoma (RCC) [Recruiting]
Randomized, Discontinuation Study of BAY 43-9006 (Sorafenib) in Patients With Advanced Refractory Cancer [Completed]
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme [Active, not recruiting]
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme [Active, not recruiting]
PROGRESS: Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib [Terminated]
Sorafenib and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Recruiting]
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors [Recruiting]
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg [Recruiting]
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma [Active, not recruiting]
Phase 1 Study With Sorafenib and Sirolimus [Recruiting]
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma [Recruiting]
Sorafenib and Cetuximab in Treating Patients With Metastatic Colorectal Cancer [Recruiting]
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors [Recruiting]
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma [Recruiting]
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye [Recruiting]
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma [Recruiting]
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Recruiting]
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery [Not yet recruiting]
Sorafenib in Treating Patients Undergoing Radical Prostatectomy for High-Risk Localized Prostate Cancer [Recruiting]
Sorafenib in Treating Patients With Metastatic Prostate Cancer [Recruiting]
Dose Escalation of Sorafenib in Patients With Advanced HCC [Recruiting]
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma [No longer recruiting]
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer [No longer recruiting]
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer [Recruiting]
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer [Recruiting]
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) [Recruiting]
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function [No longer recruiting]
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer That Cannot be Removed By Surgery [Suspended]
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer [Recruiting]
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer [Recruiting]
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer [Recruiting]
Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors [Recruiting]
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Sorafenib (BAY 43-9006) in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer [Completed]
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients [Recruiting]
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma [Recruiting]
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma [Not yet recruiting]
Sorafenib in Treating Patients With Soft Tissue Sarcomas [Recruiting]
Sorafenib in Treating Patients With Kaposi's Sarcoma [Recruiting]
Sorafenib in Treating Patients With Advanced Solid Tumors [Recruiting]
Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC) [Recruiting]
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma [Recruiting]
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. [Recruiting]
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain [No longer recruiting]
|
